Specific depressive symptoms predict remission to aripiprazole augmentation in late-life treatment resistant depression
- PMID: 28975710
- PMCID: PMC5773368
- DOI: 10.1002/gps.4813
Specific depressive symptoms predict remission to aripiprazole augmentation in late-life treatment resistant depression
Abstract
Objective: To identify which specific depressive symptoms predict remission to aripiprazole augmentation in late-life treatment resistant depression.
Methods: This is a secondary analysis of data from a late-life treatment resistant depression trial examining the safety and efficacy of aripiprazole augmentation. Participants aged 60 and above were randomized to aripiprazole augmentation (N = 91) versus placebo (N = 90). The main outcome was depression remission. Clinical predictors included individual Montgomery-Asberg Depression Rating Scale (MADRS) item scores categorized as symptomatic (scores >2) or nonsymptomatic (scores ≤2).
Results: Three MADRS items predicted depression remission with aripiprazole augmentation: symptomatic scores on sleep disturbance and nonsymptomatic scores on apparent sadness and inability to feel. The 2-way and 3-way interaction terms of these MADRS items were not significant predictors of remission; therefore, the models' ability to predict remission was not improved by combining the significant MADRS items.
Conclusions: The identification of specific depressive symptoms, which can be clinically assessed, can be used to inform treatment decisions. Older adults with treatment resistant depression that present with sleep disturbances, lack of apparent sadness, or lack of inability to feel should be considered for aripiprazole augmentation.
Keywords: MADRS; aging; aripiprazole; depression.
Copyright © 2017 John Wiley & Sons, Ltd.
Figures

Similar articles
-
Predictors and Moderators of Remission With Aripiprazole Augmentation in Treatment-Resistant Late-Life Depression: An Analysis of the IRL-GRey Randomized Clinical Trial.JAMA Psychiatry. 2016 Apr;73(4):329-36. doi: 10.1001/jamapsychiatry.2015.3447. JAMA Psychiatry. 2016. PMID: 26963689 Free PMC article. Clinical Trial.
-
Aripiprazole augmentation versus antidepressant switching for patients with major depressive disorder: A 6-week, randomized, rater-blinded, prospective study.J Psychiatr Res. 2015 Jul-Aug;66-67:84-94. doi: 10.1016/j.jpsychires.2015.04.020. Epub 2015 May 5. J Psychiatr Res. 2015. PMID: 26013203 Clinical Trial.
-
Efficacy, safety, and tolerability of augmentation pharmacotherapy with aripiprazole for treatment-resistant depression in late life: a randomised, double-blind, placebo-controlled trial.Lancet. 2015 Dec 12;386(10011):2404-12. doi: 10.1016/S0140-6736(15)00308-6. Epub 2015 Sep 27. Lancet. 2015. PMID: 26423182 Free PMC article. Clinical Trial.
-
Efficacy and safety of aripiprazole or bupropion augmentation and switching in patients with treatment-resistant depression or major depressive disorder: A systematic review and meta-analysis of randomized controlled trials.PLoS One. 2024 Apr 26;19(4):e0299020. doi: 10.1371/journal.pone.0299020. eCollection 2024. PLoS One. 2024. PMID: 38669232 Free PMC article.
-
Novel Augmentation Strategies in Major Depression.Dan Med J. 2017 Apr;64(4):B5338. Dan Med J. 2017. PMID: 28385173 Review.
Cited by
-
A Review of Therapeutics for Treatment-Resistant Depression in the Older Adult.Drugs Aging. 2023 Sep;40(9):785-813. doi: 10.1007/s40266-023-01051-3. Epub 2023 Aug 18. Drugs Aging. 2023. PMID: 37596380 Review.
-
Predicting Medication Nonadherence in Older Adults With Difficult-to-Treat Depression in the IRL-GRey Randomized Controlled Trial.Am J Geriatr Psychiatry. 2022 Sep;30(9):994-1002. doi: 10.1016/j.jagp.2022.03.002. Epub 2022 Mar 10. Am J Geriatr Psychiatry. 2022. PMID: 35393165 Free PMC article. Clinical Trial.
References
-
- American Psychiatric Association. Diagnostic and statistical manual of mental disorders 4th ed., text rev ed. Washington, DC: 2000.
-
- Baglioni C, Battagliese G, Feige B, Spiegelhalder K, Nissen C, Voderholzer U, Lombardo C, Riemann D. Insomnia as a predictor of depression: a meta-analytic evaluation of longitudinal epidemiological studies. J Affect Disord. 2011;135:10–9. - PubMed
-
- Buysse DJ, Reynolds CF, 3rd, Hoch CC, Houck PR, Kupfer DJ, Mazumdar S, Frank E. Longitudinal effects of nortriptyline on EEG sleep and the likelihood of recurrence in elderly depressed patients. Neuropsychopharmacology. 1996;14:243–52. - PubMed
-
- Callahan CM, Kroenke K, Counsell SR, Hendrie HC, Perkins AJ, Katon W, Noel PH, Harpole L, Hunkeler EM, Unutzer J, Investigators I. Treatment of depression improves physical functioning in older adults. J Am Geriatr Soc. 2005;53:367–73. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical